Satellite BroadbandSpace Technology

Gout Therapeutics Market: Technology, Trends, Development, Key Manufacturers Analysis 2018-2025

“Global Gout Therapeutics Market 2019-2025” report is to help the user understand the market in terms of its definition, influential trends, segmentation, market potential and the challenges that the market is facing.

Press Release

The global gout therapeutics market is estimated to be around 8 billion by 2025. This market has witnessed tremendous growth in last few years due to preface of various regenerative drugs and escalated acceptance of these biologics for treatment. This can be attributed to their capability to generate potent anti-inflammatory action which speeds up treatment time. Furthermore, many other drugs are currently under clinical trials which are likely to be launched in coming years which will play an important role in the market growth. Rising incidence of gout due to changes in lifestyle, growing alcohol consumption, increasing obesity and ingestion of some specific medications will drive the growth of this market. However, binding regulations and patent expiry of leading drugs will slow down the growth of global market.

Get Free Sample copy of this [email protected]

Product Outlook and Trend Analysis

Non-steroidal anti-inflammatory drugs (NSAIDs) dominates the global market because of superior level of penetration of drug, lower cost, easy availability, and ability to ease pain faster as compared to other available drugs for gout attacks. Urate lowering agents sector is expected to grow at most prominent rate during forecast period. Increasing adoption and innovation of new drugs is likely to enhance market growth. Colchicines occupies significant share in global market, due to their ability to slow down severe inflammatory response by blocking actions of neutrophils responsible for gout attacks. In 2009, FDA approved use of Colchicines for treating gout related fevers.

Regional Outlook and Trend Analysis

In 2016, the global market was dominated by North America, which can be attributed to various factors such as presence of local primary players, extensive use of gout therapies, and easily availability. U.S. dominated the regional market in 2016, followed by Canada. It is likely to sustain its leading position in the global market during the forecast period, owing to expected launch of new drugs and urate-lowering drugs. In Europe, France and Germany hold highest share for gout disease treatment drugs. Asia-Pacific is projected to witness highest growth rate due to rising incidence of gout disease, increased investments in research for the development of new and alternate therapies. Furthermore, increasing consumption of alcohol and cigarettes, changing life style, and increase in obesity rates is likely to improve growth of gout therapeutics market.

Make an enquiry before buying this [email protected]

Market Segment by Regions, regional analysis covers : Americas, United States, Canada, Mexico, Brazil, APAC, China, Japan, Korea, Southeast Asia, India, Australia, Europe, Germany, France, UK, Italy, Russia, Spain, Middle East & Africa, Egypt, South Africa, Israel, Turkey, GCC Countries.

Competitive Insights

Numerous multinational as well as local players dominate the global market. Major players comprise GlaxoSmithKline plc; Merck& Co. Inc.; AstraZeneca plc; Teijin Pharma Ltd.; Novartis AG; Takeda Pharmaceutical Company Ltd.; Savient Pharmaceuticals; and Regeneron Pharmaceuticals. Development of new and innovative products, collaborations and strategic acquisitions are some of the strategies acquired by market players to have competitive advantage over their rivals.

Market Opportunities

Major players in market are shifting their focus towards more serious gout cases in order to meet unmet medical needs of drugs for effective treatments. NSAIDs and Colchicines are expected to attract large investment due to their increasing adoption and success rate in treating acute as well as chronic gout disease. Many players have collaborated for research and development to develop more efficient drug for the treatment of gout diseases. The market will be dominated by urate lowering agents that has ability to prevent gout disease by blocking genes responsible for gout disease. With FDA approval of Zurampic (in 2015) to reduce uric acid level in blood and other new drugs in clinical trials will bring in huge opportunities for key players in the market.

Reasons to Purchase Gout Therapeutics Market Report:

  • Analysing the outlook of the Gout Therapeutics market with the recent trends and SWOT analysis.
  • Market dynamics scenario, along with growth opportunities of the Gout Therapeutics market in the years to come.
  • Gout Therapeutics Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and non-economic aspects.
  • Regional and country level analysis integrating the demand and supply forces that are influencing the growth of Gout Therapeutics market.
  • Gout Therapeutics Market value (USD Million) and volume (Units Million) data for each segment and sub-segment.
  • Competitive landscape involving the Gout Therapeutics market share of major players, along with the new projects and strategies adopted by players in the past 5 year.
  • Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major Gout Therapeutics market players.

Check the Best Discount on This [email protected]

Contact Us:
[email protected]
Ph: US – +13393375221, IN – +919881074592

This post was originally published on Space Market Research


Related Articles